The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial.
 
Sai Lan Liu
No Relationships to Disclose
 
Hai-Qiang Mai
No Relationships to Disclose
 
Dongxiang Wen
No Relationships to Disclose
 
Jin-Hao Yang
No Relationships to Disclose
 
Shan-Shan Guo
No Relationships to Disclose
 
Li-Ting Liu
No Relationships to Disclose
 
Mei-Juan Luo
No Relationships to Disclose
 
YuJing Liang
No Relationships to Disclose
 
Xue-Song Sun
No Relationships to Disclose
 
Xiao-Yun Li
No Relationships to Disclose
 
Dong-Hua Luo
No Relationships to Disclose
 
Ji-Bin Li
No Relationships to Disclose
 
Pan Wang
No Relationships to Disclose
 
Ling Guo
No Relationships to Disclose
 
Hao-Yuan Mo
No Relationships to Disclose
 
Rui Sun
No Relationships to Disclose
 
Chong Zhao
No Relationships to Disclose
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; CPPC; Hengrui Pharm; Hutchison MediPharma; Innovent Biologics; Junshi Pharmaceuticals; Keymed Biosience; Merck Serono; MSD; QiLu Pharmaceutical; Roche
 
Lin-Quan Tang
No Relationships to Disclose
 
Qiu-Yan Chen
No Relationships to Disclose